FUT4 and cancer: We observed that the MEK inhibitor “Selumetinib” caused a significant reduction of CD15/FUT4 transcript, as a consequence, CD15/FUT4-high expressing cancer cells were more sensitive to “Selumetinib” and Pimasertib” than CD15/FUT4-low counterparts.